Intas Pharmaceutical Gets CDSCO Panel Nod to Study Atorvastatin plus Fenofibrate FDC

Written By :  Dr. Divya Colin
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-07-17 12:00 GMT   |   Update On 2024-07-17 12:00 GMT
Advertisement

New Delhi: The drug major Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the bioavailability/bioequivalence (BA/BE) study of the fixed-dose combination (FDC) of atorvastatin plus fenofibrate tablets (40+145) mg.

This came after Intas Pharmaceutical presented Protocol No. 0346-22, version 01, dated 19, 2024, and Protocol No.0012-24, version 01, dated 19-1-2024.
Advertisement

Atorvastatin plus Fenofibrate belongs to the class of medicines called antilipemics (lipid-lowering medicines) primarily used in the treatment of high lipid levels (cholesterol and triglyceride levels) and prevention of heart diseases and blood vessel blockage.

Bioavailability and bioequivalence studies are required to ensure therapeutic equivalence between a pharmaceutically equivalent test drug and a generic drug or reference drug.

Atorvastatin belongs to the group of medicines called HMG-CoA reductase inhibitors, or statins. It works by blocking an enzyme that is needed by the body to make cholesterol, and this reduces the amount of cholesterol in the blood. Atorvastatin is used together with a proper diet to lower cholesterol and triglyceride (fat) levels in the blood. This medicine may help prevent medical problems (eg, chest pain, heart attack, or stroke) that are caused by fats clogging the blood vessels.

Fenofibrate is a peroxisome proliferator receptor alpha activator used to lower LDL-C, total-C, triglycerides, and Apo B while increasing HDL-C in hypercholesterolemia, dyslipidemia, and hypertriglyceridemia. Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα), increasing lipolysis, activating lipoprotein lipase, and reducing apoprotein C-III. PPARα is a nuclear receptor and its activation alters lipid, glucose, and amino acid homeostasis.

At the recent SEC meeting for cardiovascular held on June 12, 2024, the expert panel reviewed Protocol No.0346-22 version 01 dated 19-1-2024 and Protocol No.0012-24 version 01 dated 19-1-2024 presented by the drug maker Intas Pharmaceuticals.
After detailed deliberation, the committee recommended the grant of permission to carry out the BA/BE study for export purposes only.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News